Important Safety Information

  • The most common adverse reactions in clinical studies (≥ 3% of Aimovig-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig full Prescribing Information.


Indication

Aimovig is indicated for the preventive treatment of migraine in adults.

Once-monthly dosing for all Aimovig™ patients1

Designed for patients to self-administer1

Image of Aimovig™ (erenumab-aooe) SureClick Autoinjector for subcutaneous injection. Image of Aimovig™ (erenumab-aooe) SureClick Autoinjector for subcutaneous injection.

*140 mg dose = 2 x 70 mg/mL single-dose, prefilled Aimovig™ SureClick® autoinjectors.

The recommended dosage of Aimovig™ is 70 mg injected subcutaneously once monthly. Some patients may benefit from a dosage of 140 mg injected subcutaneously once monthly, which is administered as 2 consecutive subcutaneous injections of 70 mg each.1

Aimovig™ SureClick® autoinjector should be stored refrigerated at 2° C to 8° C (36° F to 46° F) in the original carton to protect from light until time of use1

If removed from the refrigerator, Aimovig™ SureClick® autoinjector can be kept at room temperature in the original carton up (up to 25°C [77°F]) for up to 7 days.
 
The single-use Aimovig™ SureClick® autoinjector allows patients to self-administer the once-monthly dose at home1
  • Doses may be administered in the upper arm, thigh, or abdomen.
    • Administration in the upper arm requires a caregiver to inject.
Injection-site reactions1
  • In clinical trials, the most frequent injection site reactions in patients treated with Aimovig™ were injection site pain, injection site erythema, and injection site pruritus.

Prescribing Aimovig™ for your patients


Image of hypothetical prescription

Show your patients this overview video on injecting Aimovig™

It is important that you thoroughly review the Instructions for Use. These instructions cover everything you need to know about how to use the Aimovig™ SureClick® autoinjector. The information in this website does not replace the Instructions for Use.

Download the Aimovig™ Patient Brochure to provide your patients with more information Product Support and Resources

Indication

Aimovig is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Please see Aimovig full Prescribing Information.

Reference: 1. Aimovig™ (erenumab-aooe) prescribing information, Amgen.